Anbio Biotechnology (NASDAQ:NNNN) Shares Down 6.9% – Time to Sell?

Anbio Biotechnology (NASDAQ:NNNN)’s share price traded down 6.9% during trading on Monday . The company traded as low as $23.01 and last traded at $23.98. 23,722 shares were traded during trading, a decline of 65% from the average session volume of 67,086 shares. The stock had previously closed at $25.76.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded shares of Anbio Biotechnology from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, February 9th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, Anbio Biotechnology currently has a consensus rating of “Hold”.

Anbio Biotechnology Price Performance

Anbio Biotechnology (NASDAQ:NNNN) last announced its quarterly earnings data on Tuesday, December 30th. The company reported $0.04 EPS for the quarter. The company had revenue of $2.29 million during the quarter.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.